• 
• 
• 

FDA News and Drug Updates

The Value of Pre–FDA Approval Healthcare Economic Information Exchange Between Payers and Drug Manufacturers

FDA News - March 2018

Actemra First FDA-Approved Treatment for CAR T-Cell–Induced Severe Cytokine Release Syndrome

Supportive Care

Supportive Care Updates from ASCO 2017 Highlighted at New Orleans Summer Cancer Meeting

Meg Barbor, MPH

A Taxing Consequence: Taxane Acute Pain Syndrome

Mark L. Zangardi, PharmD, BCOP

Helping Adolescents and Young Adults Confront Mortality

Meg Barbor, MPH

View All Supportive Care Articles

Lung Cancer

Brigatinib May Prolong Survival After Progression of Crizotinib-Refractory, ALK-Positive NSCLC

CheckMate-227 Meets Co-Primary End Point of PFS with Nivolumab/Ipilimumab Combination in NSCLC, Confirms TMB as Viable Biomarker

Treatment Paradigm Shift in ALK-Positive NSCLC Raises Further Questions Regarding ALK Inhibitor Sequencing

View All Lung Cancer Articles

Conference Correspondent

Emerging Safety Data with Checkpoint Inhibitors

Psychological Distress in Patients with Cancer Warrants Attention

Patients’ Chemotherapy-Related Side-Effect Concerns Have Evolved, But Hair Loss Remains Significant

Increased Cancer Risk in Postmenopausal Women with Central Obesity

Patients’ Fears of Radiation Side Effects Largely Unfounded

View All Conference Correspondent Articles

Most Popular Articles

PRRT—Pushing the Limits and New Directions

Conference Correspondent  - Healing NET Summit 2018

Molecular Diagnosis in NETs

Conference Correspondent  - Healing NET Summit 2018

Brigatinib May Prolong Survival After Progression of Crizotinib-Refractory, ALK-Positive NSCLC

TON Web Exclusives - Lung Cancer

Treatment Paradigm Shift in ALK-Positive NSCLC Raises Further Questions Regarding ALK Inhibitor Sequencing

TON Web Exclusives - Lung Cancer